Search results

A delegation from the Université de Namur took part in an exploratory mission to the Université Cheikh Anta Diop (UCAD) in Dakar, Senegal. The aim: to discover the research carried out in the field, meet UCAD researchers and initiate future collaborations between the two institutions.

Since September 2023, Marc Hennequart, Professor of Biochemistry and Cell Biology at UNamur, has been conducting groundbreaking research into pancreatic cancer. His team, based at the Faculty of Medicine and the Institut Narilis, studies the early stages of oncogenesis (the process of transforming a normal cell into a cancerous one) to better understand the metabolic changes behind this particularly aggressive cancer.

A major breakthrough for the health of women on oral contraceptives has been achieved by researchers in Namur. Every year in Europe, more than 22,000 cases of venous thrombosis or embolism occur among contraceptive pill users. A team of researchers from the University of Namur, in collaboration with QUALIblood (spin-off), has conducted an important study, the results of which could transform prescribing recommendations..

Bringing a new drug to market, particularly when it is intended to treat a pediatric or orphan disease, is a journey fraught with pitfalls. The ERAMET project, coordinated by Professor Flora Musuamba Tshinanu, aims to overhaul the assessment procedures, so that regulatory agencies can take innovative technologies into account and thus make more informed choices.

The TineaDiag project is a research project run by UNamur and ULiège with funding from the SPW Research Win²WAL program. It tackles dermatophytoses, skin infections responsible for ringworm, which can affect both humans and animals. The aim? To identify, in dermatophytes, precise cellular markers in order to detect them with sensitivity and certainty, and thus identify infections caused by antifungal-resistant strains.

In an ever-changing world, where health, environmental and societal crises are intertwined, it is becoming imperative to rethink health in a global and interconnected approach. It was against this backdrop that the Faculty of Medicine at the University of Namur inaugurated its new "One Health" teaching unit (UE) on Thursday February 06, 2025, in the presence of Minister Yves Coppieters. This initiative, offered to all UNamur undergraduates, aims to train tomorrow's healthcare professionals in a systemic vision, where human, animal and environmental health are considered as one and the same reality.

Helping us to age independently and in good health. This is the aim of Charlotte Beaudart's research into sarcopenia, an age-related disease that can occur as early as the age of 50. The work of the UNamur researcher and member of the Narilis Institute has been rewarded once again, as she has just been awarded the title of "Namuroise of the Year", for the Sciences category!

Beautiful victory for Margaux Mignolet, a researcher at the Faculty of Medicine's Unité de Recherche en Physiologie Moléculaire (URPhyM), who wins 1st prize in the Belgian inter-university final of the Ma thèse en 180 secondes (MT180) competition. Her research? To better understand the mechanisms of antibodies active in cases of long COVID. The second prize in this national competition was also won by a candidate from Namur. It was Petra Manja, from the Unité de Recherche en biologie des micro-organismes (URBM), Department of Biology, Faculty of Science, and is pursuing a thesis aimed at understanding resistance mechanisms in the bacterium E. coli. Both are also researchers at the NARILIS Institute.

Hepatocellular carcinoma is the most common primary liver cancer. Unfortunately, this tumor still has a high mortality rate due to the lack of effective treatments for its most advanced or poorly localized forms. As part of a partnership with the CHU UCL Namur - site de Godinne and with the support of Roche Belgium, researchers in the Department of Biomedical Sciences are trying to understand why liver tumor cells are so resistant to treatment, and to identify therapeutic alternatives to better target them.